Goldman Sachs’s Meridian Bioscience Inc VIVO Stock Holding History

Goldman Sachs’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-32,800	Closed	-$580K	–	7372
2014 Q3	$580K	Hold	32,800	–	–	﹤0.01%	5130
2014 Q2	$677K	Buy	+32,800	New	+$674K	﹤0.01%	5057

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's VIVO Position: Q1 2023 in Review

Goldman Sachs sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 1,056,680 shares — an estimated $35.1M sold.

Goldman Sachs first reported a position in VIVO in Q2 2013 and held it in 39 quarters. The position peaked at $35.1M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

Goldman Sachs reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
Goldman Sachs sold 1,056,680 Meridian Bioscience Inc shares in Q1 2023, an estimated $35.1M.
Goldman Sachs first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 39 quarters.
Goldman Sachs's Meridian Bioscience Inc position peaked at $35.1M in Q4 2022.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.